These nanoconjugates, when administered intravenously, selectively targeted CXCR4+ cancer cells, inducing their selective depletion and regression of stablished metastases in colorectal cancer models [111] and a potent blockade of tumor dissemination in mice models of AML [244, 245] and diffuse large B-cell lymphoma (DLBCL) [247]. This evidence concerns the gene CXCR4 and acute myeloid leukemia.